Strategy Asset Managers LLC Decreases Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Strategy Asset Managers LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.5% during the 4th quarter, Holdings Channel reports. The firm owned 441 shares of the biopharmaceutical company’s stock after selling 107 shares during the quarter. Strategy Asset Managers LLC’s holdings in Regeneron Pharmaceuticals were worth $314,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in REGN. Allianz SE acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $96,000. Allstate Corp purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $2,276,000. Brown Brothers Harriman & Co. raised its position in shares of Regeneron Pharmaceuticals by 9.3% during the 4th quarter. Brown Brothers Harriman & Co. now owns 527 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 45 shares during the last quarter. DnB Asset Management AS lifted its stake in Regeneron Pharmaceuticals by 8.1% in the 4th quarter. DnB Asset Management AS now owns 35,804 shares of the biopharmaceutical company’s stock valued at $25,504,000 after buying an additional 2,685 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. grew its holdings in Regeneron Pharmaceuticals by 7.6% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 92,514 shares of the biopharmaceutical company’s stock valued at $65,900,000 after buying an additional 6,510 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent research reports. Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research report on Monday, January 27th. Bernstein Bank reduced their target price on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Finally, Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $637.36 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $629.02 and a twelve month high of $1,211.20. The firm has a market capitalization of $69.68 billion, a price-to-earnings ratio of 16.65, a PEG ratio of 2.34 and a beta of 0.27. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm’s fifty day simple moving average is $683.88 and its 200 day simple moving average is $797.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 earnings per share. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.55%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.